A new insight into the treatment of renal anemia with HIF stabilizer

Table 1 Clinical characteristics of ESA and HIF stabilizer

Drug	EPO origin	EPO concentration at peak	Route	Correction of anemia	Adverse events
ESA	Exogenous	High (overshooting)	IV or SC	Correction of anemia	Hypertension thrombosis
HIF-S	Endogenous	Within physiological levels	Oral	Effective (especially, nondialysis)	Thrombosis/embolism pulmonary hypertension/ADPKD/malignancy/retinopathy/hyperkalemia hypertension?

ESA erythropoiesis stimulating agent, HIF-S HIF stabilizer, ADPKD autosomal dominant polycystic kidney disease, IV intravenous use, SC subcutaneous use

ISSN: 2059-1381